TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04882072

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion and SC injection of matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucorticoid Taper Regimen
Description: Glucocorticoid will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucorticoid Taper Regimen
Description: Glucocorticoid will be administered orally.
Study: NCT05881538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
Study: NCT05915260

Intervention type: DIAGNOSTIC_TEST
Intervention: All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion
Description: This is a observational follow up study accordingly all subjects will undergo the same examinations

Intervention type: DIAGNOSTIC_TEST
Intervention: All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion
Description: This is a observational follow up study accordingly all subjects will undergo the same examinations
Study: NCT04607135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI)
Description: Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
Study: NCT06239727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.

Intervention type: DRUG
Group type: OTHER
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Study: NCT06144749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-002
Description: Oral liquid carbon monoxide drug product.
Study: NCT05056948

Intervention type: OTHER
Intervention: artificial intelligence (AI) computer assisted design (CAD)
Description: Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
Study: NCT06122961

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06049719

Intervention type: OTHER
Intervention: NIH Task Force's Recommended Multidimensional Minimal Dataset
Description: Questionnaire
Study: NCT06122961

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06239727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (80 mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin (80 mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study: NCT06462781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Description: Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Acute and/or preventative therapeutic approaches currently used in practice
Study: NCT06437977

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT. 24Gy/3fractions Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
Study: NCT05807464

Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-15)
Study: NCT05557838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)
Study: NCT04936646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RepetitiveTranscranial Magnetic Stimulation (rTMS)
Description: The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RepetitiveTranscranial Magnetic Stimulation (rTMS)
Description: The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RepetitiveTranscranial Magnetic Stimulation (rTMS)
Description: The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
Study: NCT05645146

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation treatment delivered by Tobacco Free Florida Quitline
Description: Phone counseling with the state tobacco quitline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will be provided with a 12 week supply of nicotine patches
Study: NCT05557838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)
Study: NCT06535620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: red wine with alcohol
Description: 200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: red wine without alcohol
Description: 200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
Study: NCT05660811

Intervention type: DRUG
Group type: OTHER
Intervention: short postimplantation dual antiplatelet therapy
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet

Intervention type: DRUG
Group type: OTHER
Intervention: short postimplantation dual antiplatelet therapy
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
Study: NCT05645146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will be provided with a 12 week supply of nicotine patches
Study: NCT05660811

Intervention type: DRUG
Group type: OTHER
Intervention: extended postimplantation dual antiplatelet therapy
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: extended postimplantation dual antiplatelet therapy
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: long-term treatment with a single antiplatelet agent
Description: continuing long-term treatment with single antiplatelet agent

Intervention type: DRUG
Group type: OTHER
Intervention: long-term treatment with a single antiplatelet agent
Description: continuing long-term treatment with single antiplatelet agent

Intervention type: DRUG
Group type: OTHER
Intervention: 6 months treatment with a single antiplatelet agent
Description: continuing single antiplatelet agent up until 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: 6 months treatment with a single antiplatelet agent
Description: continuing single antiplatelet agent up until 6 months
Study: NCT05645146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Participants will be provided with a 12 week supply of nicotine lozenges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenge
Description: Participants will be provided with a 12 week supply of nicotine lozenges

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and Problem Solving (MAPS) intervention
Description: MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
Study: NCT06239207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)
Description: Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
Study: NCT04668157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granule formulation
Study: NCT06199479

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Scan
Description: Performed by MRI Scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Scan
Description: Performed by CT Scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Standard of Care Biopsy
Study: NCT06445959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV
Study: NCT06420206

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Acute Cancer Care Center)
Description: In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Goals of Care)
Description: In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
Study: NCT05660070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Social Interaction Therapy by Exposure (mSITE)
Description: mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
Study: NCT06300047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Medical Transition Coordinator
Description: Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
Study: NCT06137040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate within the first hour
Description: The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Magnesium sulfate within the first hour
Description: The control group will not receive IV magnesium sulfate within the first hour of treatment.
Study: NCT05705310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management Strategies
Description: During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
Study: NCT05372614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib Maleate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study: NCT05017116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Take orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Take orally.
Study: NCT04463719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling using the electronic conversation aid
Description: Patients receive counseling about thyroid biopsy with the use of the conversation aid.
Study: NCT05465343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 160mg orally QD
Study: NCT04463719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling by routine care
Description: Patients receive counseling by routine care without the use of the conversation aid
Study: NCT05846659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.
Study: NCT05636943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Intimacy Enhancement
Description: Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimacy Facts and Resources
Description: Self-guided booklet of readings/resources about intimacy and metastatic breast cancer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intimacy Facts and Resources
Description: Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
Study: NCT05734534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR during training
Description: Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR during training
Description: Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR during rest
Description: Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR during rest
Description: Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
Study: NCT04852198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OAGB
Description: Simplified gastric bypass procedure
Study: NCT05734534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR during rest
Description: Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
Study: NCT04852198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: Roux-en-Y gastric bypass. Standard procedure in the Netherlands
Study: NCT06236685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric impedance tomography
Description: EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric impedance tomography
Description: EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
Study: NCT04678180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined HRT and ERP
Description: tic training using the principles of HRT and ERP as to reduce tic intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined HRT and ERP
Description: tic training using the principles of HRT and ERP as to reduce tic intensity